Aktieanalys

Cantargia: New Positive Readout in NSCLC - Redeye

{newsItem.title}

Redeye Publicerad: 26 May 2023 11:56

Redeye comments on the new readout in non-small cell lung cancer presented at ASCO 2023. In particular, the complete response with nadunolimab as monotherapy is highly encouraging.

Länk till analysen i sin helhet: https://www.redeye.se/research/912624/cantargia-new-positive-readout-in-nsclc?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt